128 results
DEFA14A
CRNX
Crinetics Pharmaceuticals Inc
25 Apr 24
Additional proxy soliciting materials
4:48pm
To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending … % FOR WITHHOLD FOR FOR FOR AGAINST ABSTAIN 2. To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered
S-3ASR
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Automatic shelf registration
4:05pm
and incorporate by reference, market data and industry statistics and forecasts that are based on independent industry publications and other publicly … and the documents incorporated by reference herein also contain estimates and other statistical data made by independent parties and by us relating
S-3ASR
EX-23.1
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Automatic shelf registration
4:05pm
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Prospectus
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
or otherwise. This presentation also contains information gathered from market research, estimates and other statistical data made by independent parties
8-K
EX-10.1
g39kp9du y5
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-10.2
110 swsvn3
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
S-8
cqubghv04v42 83so9w7
28 Feb 24
Registration of securities for employees
6:04pm
S-8
EX-23.2
l148pipn70ox94 b729b
28 Feb 24
Registration of securities for employees
6:04pm
8-K
EX-99.1
nabcnf0s mfn3
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.2
wxbe vah5rg9kr
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-3.1
bjsekne127yzwu1n12mn
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm
S-8
dkwyzps
7 Nov 23
Registration of securities for employees
4:31pm
S-8
EX-23.2
wzox lckqkf
7 Nov 23
Registration of securities for employees
4:31pm
8-K
EX-1.1
f8rzs0tvck
13 Sep 23
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
5:23pm
424B5
emg7 9ltyzkvgluk
13 Sep 23
Prospectus supplement for primary offering
5:19pm
424B5
8vp9ne3nyfp5
11 Sep 23
Prospectus supplement for primary offering
4:09pm